In a report issued on January 24, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC – Research Report), with a price target of $33.00. The company’s shares closed last Monday at $28.40. According to TipRanks.com, Prasad is a 4-star analyst with an average return of 16.6% and a 70.0% success rate. Prasad covers the Healthcare sector, focusing on stocks […]
Alzheimer’s disease has long been associated with the harmful proteins amyloid beta and tau. They clump up in the brain, disrupting neurons and causing memory loss and other symptoms. Researchers at Temple University’s Lewis Katz School of Medicine say they’ve found a new way to prevent amyloid beta and tau from building up in the […]
– The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price – Inclisiran, The Medicines Company’s investigational, innovative, potent twice-annual therapy to lower LDL cholesterol, has potential to transform treatment of cardiovascular […]
“This beautiful study shows, for the first time, a close association between T cells, cognition, and neurodegenerative disease in humans,” wrote Jonathan Kipnis of University of Virginia in Charlottesville. “These elegant findings on expansion of Epstein-Barr virus-reactive CD8 T cells in the CSF of AD patients are extremely interesting and intriguing,” he added. More at: […]
Patients with the ultra-rare disease FOP grow bone where it doesn’t belong, creating a life-threatening second skeleton. Regeneron Pharmaceuticals believes it can offer hope: A new treatment reduced new bone growth by 90% in a clinical trial, the company said, a result that could lead to Food and Drug Administration approval. More at: https://www.statnews.com/2020/01/09/regeneron-drug-reduces-bone-growth-rare-skeletal-disease/
For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is the Buzz of BIO 2020 winner in the Public Therapeutic Biotech category. The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential to improve lives. The event also is an opportunity to make investor […]
Social media is a fantastic development in human communications. However, as with any technology, security should not be an afterthought. Here is a very good list of simple security steps everyone should consider. https://www.networkworld.com/article/2870409/12–tips-for-safe-social-networking.html#slide4
How to vote: 1. Go here – https://convention.bio.org/buzzofbio-vote/ 2. Complete each field on the right side of the page 3. Select Treventis Corporation under Technologies of Tomorrow 4. Hit submit
UPDATED: Biogen’s Alzheimer’s drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads More at https://endpts.com/biogens-alzheimers-drug-aducanumab-implodes-in-a-phiii-disaster/
Elephants have evolved extra copies of a gene that fights tumour cells, according to two independent studies1, 2 — offering an explanation for why the animals so rarely develop cancer. Why elephants do not get cancer is a famous conundrum that was posed — in a different form — by epidemiologist Richard Peto of the University of Oxford, UK, […]